Abstract:<p>Illicitly manufactured fentanyl and its analogs (i.e., fentanyl-related compounds) have flooded the street drug market in recent years and the continuing rise in opioid-related overdose deaths in the United States (U.S.) is now attributed primarily to these compounds. In response to this crisis, the U.S. Drug Enforcement Administration (DEA) enacted a 2-year emergency class-wide ban on fentanyl-related compounds by temporarily placing them into Schedule I of the Controlled Substances Act, meaning that these compounds have high abuse potential but no approved therapeutic use (Docket No. DEA-476 21 CFR Part 1308; Federal Register Vol 83, No. 25, February 6, 2018). The initial temporary class-wide scheduling of fentanyl-related compounds was re-authorized on February 6, 2020 and will remain in effect until May 6, 2021. While this action is understandable from a law enforcement perspective because it theoretically will make it easier to prosecute those who illicitly manufacture these substances, it is likely to have several unintended consequences from a scientific and medical perspective that may hamper our ability to combat the opioid crisis in the long run. The current paper describes these unintended consequences. The main problem with class-wide bans is that potentially thousands of compounds are defined solely by their chemical structures without regard for their pharmacological activity. As such, an antagonist (i.e., a medication that could be used to reverse an overdose but would not produce a drug "high") could be mistakenly included in the class-wide ban. Another unintended consequence of a class-wide ban on synthetic fentanyl-like compounds is that the regulatory burden may complicate the development of novel medical interventions such as vaccines and monoclonal antibodies for treating opioid use disorders (OUD) and preventing fentanyl-related overdoses. There is much that we do not understand about how to most effectively treat fentanyl-related overdoses and OUD so any regulatory effort hindering research in this area will be counterproductive in the long term.</p>

Structure-Based Engineering of Monoclonal Antibodies for Improved Binding to Counteract the Effects of Fentanyl and Carfentanil

Structure-Activity Relationships of the Fentanyl Scaffold: Identification of Antagonists as Potential Opioid Overdose Reversal Agents

Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse

Molecular Pharmacology Profiling of Phenylfentanil and Its Analogues to Understand the Putative Involvement of an Adrenergic Mechanism in Fentanyl-Induced Respiratory Depression

Are carfentanil and acrylfentanyl naloxone resistant?

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

Blocking Potential Metabolic Sites on NAT to Improve Its Safety Profile While Retaining the Pharmacological Profile

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators

Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression

Fentanyl Structure as a Scaffold for Opioid/Non-Opioid Multitarget Analgesics

Effectiveness Comparisons of G-protein Biased and Unbiased Mu Opioid Receptor Ligands in Warm Water Tail-Withdrawal and Drug Discrimination in Male and Female Rats

Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys

Countermeasures for Preventing and Treating Opioid Overdose

Fentanyl-Type Antagonist of the μ-Opioid Receptor: Important Role of Axial Chirality in the Active Conformation

Potential unintended consequences of class-wide drug scheduling based on chemical structure: A cautionary tale for fentanyl-related compounds

Correspondence of fentanyl brain pharmacokinetics and behavior measured via engineering opioids biosensors and computational ethology

Structural basis of μ-opioid receptor targeting by a nanobody antagonist

Development of a Translational Model to Assess the Impact of Opioid Overdose and Naloxone Dosing on Respiratory Depression and Cardiac Arrest

Designing immunotherapies to thwart drug abuse

The Rising Crisis of Illicit Fentanyl Use, Overdose, and Potential Therapeutic Strategies